<DOC>
	<DOCNO>NCT01541709</DOCNO>
	<brief_summary>KIT exon 9 mutant poor survival compare KIT exon 11 mutant treat dose imatinib , 400 mg per day , patient KIT exon 9 mutation well progression-free survival imatinib treatment escalate dose , 800 mg per day , imatinib treatment dose 400 mg per day.10,11 Based result , imatinib 800 mg per day consider standard dose treatment patient metastatic unresectable GIST show KIT exon 9 mutation Western country .</brief_summary>
	<brief_title>Imatinib Dose Escalation 800 mg/Day Korean Patients With Metastatic Unresectable GIST Harboring KIT Exon 9 Mutation</brief_title>
	<detailed_description>According previous prospective phase II study imatinib 400 mg per day metastatic unresectable GIST , hematologic non-hematologic toxicity frequent Korean patient compare Western studies.7 It may cause relatively high exposure imatinib per body surface area Korean patient Western population weight height Korean patient relatively small Western people . So , plan start imatinib 400 mg per day sequentially escalate dos imatinib study .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age 18 old Histologically confirm metastatic unresectable GIST CD117 ( + ) , DOG1 ( + ) , KIT mutation ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) 0~2 Primary mutation KIT exon 9 Imatinib treatment le 4 week first dose 400 mg per day No prior use tyrosine kinase inhibitor ( ( , patient recurrence 6 month completion adjuvant imatinib dose 400 mg per day enrol study ) At least one evaluable disease RECIST v1.0 Resolution toxic effect prior treatment ( chemotherapy , surgery , RFA ( radiofrequency ablation ) , radiotherapy , and/or TACE ) Adequate bone marrow function define platelet ≥ 75 x 109/L neutrophil ≥ 1.5 x 109/L ( within 1 week prior first dose imatinib 400 mg per day ) Adequate renal function , serum creatinine &lt; 1.5 x ULN ( within 1 week prior first dose imatinib 400 mg per day ) Adequate hepatic function serum total bilirubin &lt; 1.5 x ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x UNL presence liver metastasis ( within 1 week prior first dose imatinib 400 mg per day ) No malignant disease apart nonmelanotic skin cancer carcinoma situ uterine cervix cancer except treat curative intent &gt; 5 year previously without evidence relapse Provision sign write informed consent Severe comorbid illness and/or active infection Pregnant lactate woman History malignancy except basal cell carcinoma carcinoma situ uterine cervix CNS metastasis Clinically significant bleeding GI tract GI obstruction malabsorption Known hypersensitivity imatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>This single-center</keyword>
	<keyword>prospective</keyword>
	<keyword>single-arm</keyword>
	<keyword>open-label phase II study</keyword>
</DOC>